Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 3/20 | 0.43 |
| ▸ | CDK2 | P24941 | 3/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | ABL1 | P00519 | 2/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.40 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.40 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | PRKCG | P05129 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | FES | P07332 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5578150 | 0.93 | CDK1 (0.45) | CDK1CDK2CCNB1CCNA2CCNA1 | |
| SCHEMBL5578275 | 0.91 | JAK2 (0.46) | CDK1CDK2CCNB1CCNA2CCNA1 | |
| SCHEMBL5578220 | 0.88 | CDK1 (0.41) | CDK1CDK2CCNB1CCNA2CCNA1 | |
| SCHEMBL5579242 | 0.86 | ABL1 (0.38) | CDK1CDK2MEN1KMT2AABL1 | |
| SCHEMBL5578274 | 0.85 | NPC1 (0.43) | CDK2ABL1ROCK1MAP4K4EGFR | |
| SCHEMBL5578316 | 0.85 | RAB9A (0.50) | MEN1KMT2AMAPTHTTALDH1A1 | |
| SCHEMBL5578239 | 0.82 | THRB (0.41) | CDK1CDK2MEN1KMT2AABL1 | |
| SCHEMBL14511655 | 0.80 | CDK1 (0.44) | CDK1CDK2CCNB1CCNA2CCNA1 | |
| SCHEMBL5579217 | 0.80 | MEN1 (0.41) | CDK1CDK2CCNB1CCNA2CCNA1 | |
| SCHEMBL12659647 | 0.80 | MAPT (0.39) | MEN1KMT2AMAPTTHRBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070105900-A1 | Pharmaceutical compounds | ATEX THERAPEUTICS, LIMITED (GB) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105900-A1 | Pharmaceutical compounds | AURKA, AURKC, CDK1 | CDK1 3/4885CDK2 5/4885CCNB1 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.